EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Interleukin 6 Levels in Severe COVID-19 Patients

Yıldız OKUTURLAR, İftihar KÖKSAL, Yasemin GÜNDOĞDU, Arzu YÜKSEL, Özgür OKUTURLAR, Fadıl HAVAS, Cem GUN

DAHUDER Medical Journal · 2023

DOI: 10.56016/dahudermj.1220959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift DAHUDER Medical Journal, 2023. Verfasst von Yıldız OKUTURLAR und 6 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Interleukin 6 (IL-6) plays a leading role in the proliferation and differentiation of immune cells. Level of IL-6 is manifestly increased under many inflammatory conditions, including cytokine release syndrome. We evaluated the IL-6 levels of patients who were hospitalized with the diagnosis of COVID-19.

Methods

In the study, the test results of 19 cases whose IL-6 levels were measured between March 11, 2020 and May 31, 2020 retrospectively. The inpatients in the covid service (Group 1) and the patients admitted to the Intensive Care Unit (ICU) of our hospital (Group 2) were compared and evaluated. In addition, patients with positive and negative RT-PCR test results were checked for IL-6.

Results

While 8 (Group 1) of 19 patients observed in the clinic were transferred to the ICU, 11 patients (Group 2) were observed in the covid service until their discharge. Group 1 IL-6 levels (median 34 pg/mL) and Group 2 IL-6 levels (median 116 pg/mL) were found to be high in both groups (p = 0,099). However, it was found to be significantly higher in patients with positive COVID-19 RT-PCR test (median 90.60 pg/mL) than in negative patients (median 29.90 pg/mL) (p = 0.018).

Conclusion

No significant difference in IL-6 levels between the patients who were monitored in the clinic and transferred to the ICU was found in this study. The significant difference between IL-6 levels among COVID-19 RT-PCR positive and negative patients reveals the importance of IL-6 level with regard to tocilizumab treatment in COVID-19 patients in cytokine storm. Keywords: COVID-19, Interleukin 6, Cytokine Storm, Macrophage Activation Syndrome

Zitieren

APA

OKUTURLAR, Y., KÖKSAL, İ., GÜNDOĞDU, Y., YÜKSEL, A., OKUTURLAR, Ö., HAVAS, F., & GUN, C. (2023). Evaluation of Interleukin 6 Levels in Severe COVID-19 Patients. DAHUDER Medical Journal. https://doi.org/10.56016/dahudermj.1220959

Vancouver

OKUTURLAR Y, KÖKSAL İ, GÜNDOĞDU Y, YÜKSEL A, OKUTURLAR Ö, HAVAS F, et al. Evaluation of Interleukin 6 Levels in Severe COVID-19 Patients. DAHUDER Medical Journal. 2023. doi:10.56016/dahudermj.1220959

BibTeX
@article{OKUTURLAR2023,
  author = {OKUTURLAR, Yıldız and KÖKSAL, İftihar and GÜNDOĞDU, Yasemin and YÜKSEL, Arzu and OKUTURLAR, Özgür and HAVAS, Fadıl and GUN, Cem},
  title = {Evaluation of Interleukin 6 Levels in Severe COVID-19 Patients},
  journal = {DAHUDER Medical Journal},
  year = {2023},
  doi = {10.56016/dahudermj.1220959}
}
Kostenlos starten →